Date: 2015-09-30
Type of information: IPO
Company: Nabriva Therapeutics (Austria)
Investors:
Amount: $ 92.5 million
Funding type: IPO
Planned used: Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans.
Others: * On September 30, 2015, Nabriva Therapeutics announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 1,350,000 American Depositary Shares (ADSs), representing 135,000 of Nabriva's common shares, at the initial public offering price of $10.25 per ADS, less underwriting discounts. All of the ADSs in the offering were sold by Nabriva. After the over-allotment closing, the total number of ADSs sold by Nabriva in its initial public offering increased to 10,350,000 ADSs, which resulted in gross proceeds of approximately $106.1 million and net proceeds of approximately $92.2 million, after deducting underwriting discounts and estimated offering expenses. Leerink Partners LLC and RBC Capital Markets, LLC acted as joint book-running managers for the offering. Needham & Company, LLC and Wedbush PacGrow acted as co-managers. * On September 23, 2015, Nabriva Therapeutics announced the closing of its initial public offering of 9,000,000 American Depositary Shares (ADSs), representing 900,000 of its common shares, at a public offering price of $10.25 per ADS, before underwriting discounts. All of the ADSs in the offering were sold by Nabriva. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 17, 2015. * On September 17, 2015, Nabriva Therapeutics announced the pricing of its initial public offering of 9,000,000 American Depositary Shares (ADSs), representing 900,000 of its common shares, at a public offering price of $10.25 per ADS, before underwriting discounts. All of the ADSs are being sold by Nabriva. In addition, Nabriva has granted the underwriters an option for a period of 30 days to purchase up to 1,350,000 additional ADSs at the public offering price, less the underwriting discount. Nabriva\'s ADSs have been approved for listing on the NASDAQ Global Market and are expected to begin trading under the ticker symbol \"NBRV\" on September 18, 2015. Leerink Partners LLC and RBC Capital Markets, LLC are acting as joint book-running managers for the offering. Needham & Company, LLC and Wedbush PacGrow are acting as co-managers.
Therapeutic area: Infectious diseases
